| 张耀耀,刘云霞,程淼,王慧兰.复方苦参注射液联合化疗治疗晚期胃癌的Meta分析[J].浙江中西医结合杂志,2021,31(8): |
| 复方苦参注射液联合化疗治疗晚期胃癌的Meta分析 |
| Meta-analysis of Compound Kushen Injection combined with chemotherapy in the treatment of advanced gastric cancer |
| 投稿时间：2021-02-04 修订日期：2021-06-28 |
| DOI： |
| 中文关键词: 复方苦参注射液 化疗 晚期胃癌 Meta分析 |
| 英文关键词:Compound Kushen Injection chemotherapy advanced gastric cancer Meta-analysis |
| 基金项目: |
|
| 摘要点击次数: 836 |
| 全文下载次数: 26 |
| 中文摘要: |
| 目的 对复方苦参注射液联合化疗治疗晚期胃癌的有效性和安全性进行Meta分析。 方法 计算机检索中文期刊全文数据库（CNKI）、万方数据库（Wanfang）、维普数据库（VIP）、中国生物医学文献数据库（CBM）、PubMed、The Cochrane Library，检索时限均为各个数据库建库至2020年11月，收集有关复方苦参注射液联合化疗治疗晚期胃癌临床随机对照试验。参照Cochrane系统评价手册5.1.0标准，由两名研究者独立评价文献质量并交叉核对后，使用RevMan 5.3软件进行Meta分析。结果 纳入27个随机对照试验，2213例患者，其中复方苦参注射液联合化疗方案（试验组）1120例，单纯化疗方案（对照组）1093例。Meta分析结果显示：与单纯化疗相比，复方苦参注射液联合化疗能显著提高晚期胃癌患者的近期疗效[RR=1.40，95%CI（1.27,1.55），P＜0.00001]，显著改善患者的生活质量[RR=1.64，95%CI(1.43,1.87)，P＜0.00001]，减少白细胞下降[RR=0.63，95%CI(0.57,0.71)，P＜0.00001]、血小板下降[RR=0.62,95%CI(0.53,0.73)，P＜0.00001]、血红蛋白下降[RR=0.59，95%CI(0.48,0.73)，P＜0.00001]、胃肠道不良反应[RR=0.62，95%CI(0.53,0.71)，P＜0.00001]、肝功能损伤[RR=0.47，95%CI(0.39,0.56)，P＜0.00001]、肾功能损伤[RR=0.45，95%CI(0.26,0.75)，P=0.003]、周围神经毒性[RR=0.51，95%CI(0.40,0.64)，P＜0.00001]的发生率。结论 复方苦参注射液联合化疗治疗晚期胃癌，可增加化疗的近期疗效，提高患者生活质量、降低化疗药物不良反应发生率。 |
| 英文摘要: |
| AIM To systematically evaluate the efficacy and safety of compound Kushen injection combined with chemotherapy in the treatment of advanced gastric cancer. ME-THODS The computer retrieves PubMed, The Cochrane Library, Chinese Journal Full-text Database (CNKI), Wanfang Database, VIP Database (VIP), and China Biomedical Literature Database (CBM). The search time is built until November 2020. A randomized controlled trial of compound Kushen injection combined with chemotherapy in the treatment of
advanced gastric cancer was included. Two investigators independently evaluated the quali-ty of the literature, extracted the data and cross-checked according to the Cochrane Syst-em Evaluation Manual 5.1.0, and then used the RevMan 5.3 software for meta-analysis.RESULTS Twenty-seven randomized controlled trials were included in 2,213 patients. Meta-ana-lysis results show that combined with Kushen injection combined with chemotherapy can significantly improve the short-term effect of patients with advanced gastric cancer[RR=1.40，95%CI（1.27,1.55），P＜0.00001], significantly improve the quality of life of patients[RR=1.64,95%CI(1.43,1.87),P＜0.00001],reduce the incidence of leukopenia[RR=0.63，95%CI(0.57,0.71)，P＜0.00001], thrombocytopenia[RR=0.62,95%CI(0.53,0.73)，P＜0.00001], hemoglobin decli-ne[RR=0.59，95%CI(0.48,0.73)，P＜0.00001], gastrointestinal adverse reactions[RR=0.62,95%CI(0.53,0.71),P＜0.00001], liver damage[RR=0.47，95%CI(0.39,0.56),P＜0.00001],renal impairme-nt[RR=0.45,95%CI(0.26,0.75),P=0.003], peripheral neurotoxicity[RR=0.51，95%CI(0.40,0.64),P＜0.00001].CONCLUSION Compound Kushen injection combined with chemotherapy for ad-vanced gastric cancer can increase the short-term efficacy of chemotherapy, improve the quality of life of patients, and reduce the incidence of adverse reactions of chemotherapy drugs. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
